logo-loader
NASDAQ:ACIU

AC Immune SA

Receive alerts
Market:
NASDAQ
Price
2.10 USD
Day Change
-0.47%
Market Cap:
$208.8 m
52 weeks high
3.90
52 weeks low
2.02

In brief

AC Immune is a clinical stage biopharmaceutical company developing a pipeline of products, including both active immunotherapies and small molecules, targeting key misfolded proteins and pathways for the treatment of multiple neurodegenerative diseases. The company has a growing focus on its wholly owned proprietary clinical-stage programs, including: ACI-7104, an active immunotherapy targeting -synuclein (-syn) in Parkinson's disease; and ACI-19764, a small molecule inhibitor of the NLRP3 inflammasome.